The Chairman and CEO of Pfizer, Albert Bourla, delivered a speech on May 22, 2024 in the Wall Street Journal in New York City, USA.
Andrew Kelly | Reuters
Boring Tuesday Report In the fourth quarter, the revenue and income estimates, because the sales of the company’s common products exceeded expectations, its extensive reduction of cost efforts was held.
According to LSEG’s survey of analysts, the company reported in the fourth quarter in the fourth quarter:
- Earnings per share: 63 Metropolitan adjustment and expected 46 cents
- income: 17.76 billion US dollars and expected US $ 17.36 billion
Pfizer’s stock rose by 2 % in the listing transaction on Tuesday.
As a result, Pfizer’s key year is limited, and Pfizer is pursuing a wide range of costs because it comes from The rapid decline in its common business And the stock price of the past two years. The company in December It means expected to save $ 500 million This year is based on its cost reduction plan.
The company booked a net income of $ 410 million in the fourth quarter, or 7 cents per share. In contrast, the same period a year ago, the net loss was 3.37 billion US dollars, or a loss of 60 cents per share.
It does not include certain items, including reorganization costs and cost -related costs related to intangible assets. The company’s earnings per share are 63 cents in the quarter.
Pfizer reported that the revenue in the fourth quarter was 17.76 billion US dollars, an increase of 22 % over the same period last year.
The company reiterated its annual outlook it provided in December with a forecast of sales of 61 billion to 64 billion US dollars, similar to the sales of COVID products similar to 2024. Pfizer pointed out, Change the Medicare Program Sales generated by reducing the inflation law will damage the sales of $ 1 billion.
The company dives in one -time items, and is expected to be between 2.80 and $ 3 per share in 2025.
However, Wall Street may be more concerned about Pfizer’s long -term financial situation and its drug channels. Investors are still observing whether Pfizer can win the booming weight loss pill market through its daily version of Danuglipron, a daily version of Danuglipron.
Boring It seems to have escaped At present, the fighter battle with the agency battle with the aggressive investor Starboard Value is worth about $ 1 billion in stakes. The deadline has passed this year’s nominated board member.
COVID product defeat estimate
The fourth quarter of Pfel’s fourth quarter was because the demand for its common products was higher than expected.
Its antiviral PAXLOVID brought $ 727 million in sales this quarter, and this was a $ 3.1 billion income loss recorded during the year. But the same quarter last year included revenue reversal related to plan returns About 6.5 million PaxLovid doses From the US government.
Pfizer said that this growth is driven by strong demand, especially during the recent period of the United States, and the one -time contract was delivered to 1 million Paxlovid to the Federal Federal Treatment courses provided by the government. According to Streetaccount data, analysts expect the drug to sell at $ 630 million.
The company’s COVID SHOT reserved $ 3.4 billion in revenue, a decrease of $ 2 billion over the same period a year ago. Pfizer said that the main reason for the decline is that the global co -vaccine vaccination amount is less and its radio dosage is low.
According to Streetaccount, analysts are expected to sell $ 3 billion.
